Menstrual health and hormonal care are two important segments of the gynaecology pharmaceutical market. From painful periods and heavy menstrual bleeding to PCOS and hormonal irregularities, women may require different medical approaches depending on their symptoms, diagnosis and stage of life.
For pharmaceutical distributors exploring a Gynae PCD Pharma Franchise, understanding these therapeutic segments is essential. A well-planned product portfolio can cover multiple women's healthcare requirements while helping distributors build a focused presence in the gynaecology market.
But what types of products are included in menstrual health and hormonal care? Which formulations should distributors understand? And what should they evaluate when choosing a pharmaceutical company?
This guide explores the key product categories, their therapeutic relevance and selected products from the Moruf Lifesciences portfolio.
Menstrual health involves the regularity, duration, flow and symptoms associated with the menstrual cycle. Hormonal care, on the other hand, covers medicines and formulations used in the management of selected conditions involving reproductive hormones and endocrine function.
These areas are closely connected. Hormonal changes can influence menstrual patterns, while conditions such as polycystic ovary syndrome (PCOS) may affect ovulation and cycle regularity.
However, not every menstrual concern is caused by a hormonal imbalance. Heavy bleeding, irregular periods and menstrual pain can have several underlying causes, which is why appropriate medical assessment is important before treatment.
For pharmaceutical businesses, these categories represent an important part of a specialised women's healthcare portfolio.
Painful periods and heavy menstrual bleeding are common reasons women seek gynaecological care. Depending on the diagnosis, doctors may consider non-hormonal medicines, hormonal treatments or other interventions.
Two important medicine categories in this segment are:
Non-steroidal anti-inflammatory drugs (NSAIDs): Certain NSAIDs, including mefenamic acid, are used to manage menstrual pain. They work by reducing prostaglandin production, which is involved in uterine contractions and pain.
Antifibrinolytic medicines: Tranexamic acid is prescribed in selected cases of heavy menstrual bleeding. It helps reduce blood loss by supporting the stability of blood clots.
Nexic-M: A combination of tranexamic acid and mefenamic acid, listed in Moruf's catalogue for this therapeutic area.
Nexic-500: Contains tranexamic acid 500 mg.
Drowar-M: Contains drotaverine 80 mg and mefenamic acid 250 mg.
These products represent different formulation approaches within menstrual and pain-management care. Their use depends on the patient's diagnosis, medical history and prescribing decision.
For distributors, understanding the difference between a product containing an NSAID, an antifibrinolytic or an antispasmodic is important when studying a gynaecology product portfolio.
Polycystic ovary syndrome (PCOS) is a common hormonal and metabolic condition that can affect ovulation, menstrual regularity and androgen levels. Some women may also experience acne, excess facial or body hair, and difficulty conceiving.
PCOS management is individualised. Depending on the patient's symptoms and treatment goals, a healthcare professional may consider lifestyle measures, hormonal medicines, metabolic management or fertility-related treatment.
Product categories in this area may include:
Formulations containing myo-inositol and D-chiro-inositol.
Selected metabolic medicines.
Hormonal preparations prescribed for specific menstrual concerns.
Nutritional formulations used where clinically appropriate.
FERJOY-PCO
Moruf lists FERJOY-PCO with the following composition:
Myo-inositol 550 mg
D-chiro-inositol 13.8 mg
Chromium 100 mcg
Metformin HCl 500 mg
L-methylfolate calcium 0.5 mg
Mecobalamin 750 mcg
FERJOY-IN
The listed composition includes myo-inositol 550 mg, D-chiro-inositol 13.8 mg, chromium 100 mcg and vitamin D3 200 IU.
These products are offered by Moruf's PCOS-related and women's hormonal healthcare portfolio. Their compositions and approved indications should be reviewed individually; they should not be treated as interchangeable or as universal solutions for PCOS.
For a distributor evaluating a Gynae PCD Pharma Franchise, the availability of products in this segment can be an important consideration when assessing the company's women's healthcare range.
Progesterone and other reproductive hormones play important roles in the menstrual cycle and reproductive health.
Certain progesterone or progestogen formulations are prescribed for specific clinical situations, which may include selected menstrual disorders and other reproductive-health requirements.
This segment may include:
Dydrogesterone formulations.
Other prescribed progestogen preparations.
The specific medicine, dosage and duration depend on the indication. These products should not be used interchangeably, as their pharmacological properties and approved uses may differ.
Moruf's catalogue includes several products in this category:
| Product | Listed composition |
|---|---|
| MOPREG-200 | Natural micronised progesterone 200 mg |
| MOPREG-400 | Natural micronised progesterone 400 mg |
| MOPREG-200 SR | Natural micronised progesterone 200 mg sustained-release tablet |
| MYTERMCARE-10 | Dydrogesterone 10 mg |
| MYTERMCARE-20 SR | Dydrogesterone 20 mg sustained-release tablet |
| MYTERM-5 | Allylestrenol 5 mg |
The MOPREG and MYTERMCARE ranges provide examples of different progesterone and progestogen formulations within Moruf's portfolio.
For pharmaceutical distributors, this category demonstrates why a company's product catalogue should be evaluated beyond brand names. Composition, dosage form, strength, approved indication and product documentation all matter.
Hormonal contraceptives are used for pregnancy prevention. Depending on the formulation, they may also be prescribed for selected menstrual or hormonal concerns.
Combined oral contraceptives generally contain an oestrogen and a progestin. Different combinations have different characteristics, contraindications and prescribing considerations.
Moruf's published catalogue includes:
MORUF-DE: Desogestrel 0.15 mg + ethinylestradiol 0.03 mg.
MORUF-LE: Levonorgestrel 0.15 mg + ethinylestradiol 0.03 mg.
MORUF-PILL: Drospirenone 3 mg + ethinylestradiol 0.03 mg.
These formulations belong to the hormonal contraception category. The selection of a contraceptive depends on individual medical suitability, including relevant risk factors and contraindications.
Distributors should understand the differences between the compositions and strengths rather than treating all hormonal contraceptive products as identical.
Some progestogen medicines are prescribed for specific menstrual and gynaecological conditions. Norethisterone, for example, is used in selected cases of menstrual disorders and abnormal uterine bleeding.
The indication and treatment schedule are determined by the prescribing clinician.
Moruf's catalogue includes:
RENORTH-5: Norethisterone 5 mg.
RENORTH-10 CR: Norethisterone 10 mg.
RENORTH-15 CR: Norethisterone acetate 15 mg controlled-release tablet.
These products represent different strengths and formulations within the progestogen category. Their approved indications and release characteristics should be checked against the current product documentation.
For a Gynae PCD Pharma Franchise distributor, having a clear understanding of the product range helps when organising a portfolio by therapeutic segment.
Women's healthcare portfolios may also include nutritional formulations containing vitamins, minerals and other ingredients. These products are distinct from prescription hormonal medicines and should be evaluated according to their composition and approved claims.
Depending on the formulation, such products may be positioned for specific nutritional requirements or as part of a healthcare professional's broader management plan.
FERJOY-M
Moruf lists a formulation containing Coenzyme Q10, astaxanthin, zinc, L-carnitine, lycopene, glutathione, selenium and vitamin C.
FERJOY-F
This formulation includes ingredients such as L-arginine, folic acid, vitamin B12, vitamin D3, zinc, selenium, N-acetyl cysteine, Coenzyme Q10, chasteberry and myo-inositol.
MOROSE-E-1000
Moruf lists evening primrose oil 1000 mg with natural vitamin E 150 mg.
These products have different compositions and should not be assumed to have the same purpose or clinical role. Distributors should refer to the product's approved information and avoid making unsupported claims about hormonal balance, fertility or treatment outcomes.
A specialised women's healthcare portfolio can cover several distinct therapeutic areas. For distributors, this can provide a more structured approach to understanding the gynaecology market.
Some important considerations include:
1. Coverage across therapeutic categories
A portfolio that includes menstrual pain management, heavy menstrual bleeding, PCOS-related formulations and hormonal preparations can address a wider range of prescription categories.
2. Multiple formulations and strengths
Different dosage forms and strengths serve different prescribing requirements. Distributors should understand the exact composition and formulation of every product.
3. Better product knowledge
Understanding the difference between tranexamic acid, mefenamic acid, progesterone, dydrogesterone and contraceptive combinations helps distributors communicate product information accurately.
4. Consistent product availability
Reliable stock availability and supply planning are important when developing long-term relationships with pharmacies and healthcare professionals.
5. Clear product documentation
Product permissions, approved indications, labelling, manufacturing details and quality documentation should be checked before selecting a franchise partner.
Choosing the right pharmaceutical partner is an important step for distributors entering the women's healthcare segment. A large catalogue alone does not establish that a company is the right business partner.
Before selecting a Gynae PCD Pharma Franchise Company, consider the following:
| Factor | What distributors should evaluate |
|---|---|
| Product range | Availability across menstrual health, PCOS and hormonal care |
| Product composition | Clear details of ingredients, strengths and dosage forms |
| Quality documentation | Applicable manufacturing and quality records |
| Product permissions | Relevant licences and product-specific documentation |
| Supply reliability | Stock availability and delivery arrangements |
| Promotional support | Product literature and marketing materials |
| Commercial terms | Pricing, minimum order quantities and payment conditions |
| Monopoly rights | Territory, products covered and written exclusivity terms |
A transparent Gynae PCD Pharma Franchise Company should be able to explain its product portfolio and commercial arrangements clearly. Distributors should independently verify the relevant documentation and terms before entering into a business agreement.
Moruf Lifesciences focuses on gynaecology and women's healthcare, with a published product catalogue covering menstrual health, PCOS-related care, hormonal formulations, fertility and nutritional healthcare.
Its menstrual and hormonal care portfolio includes products such as:
Nexic-M and Nexic-500 – tranexamic acid-based formulations.
Drowar-M – drotaverine and mefenamic acid combination.
FERJOY-PCO and FERJOY-IN – formulations listed in the PCOS-related healthcare segment.
MOPREG range – natural micronised progesterone formulations.
MYTERMCARE range – dydrogesterone formulations.
MORUF-DE, MORUF-LE and MORUF-PILL – hormonal contraceptive formulations.
RENORTH range – norethisterone-based formulations.
This range gives distributors several product categories to evaluate when considering a specialised women's healthcare business.
If you are looking for a Gynae PCD Pharma Franchise, explore Moruf Lifesciences' product catalogue and review the available franchise opportunities, product documentation, territory terms and supply arrangements.
Menstrual health medicines may include products containing tranexamic acid for selected cases of heavy menstrual bleeding, NSAIDs such as mefenamic acid for menstrual pain, and hormonal preparations prescribed for specific menstrual disorders.
Moruf's catalogue includes Nexic-M, Nexic-500 and Drowar-M, among other products relevant to menstrual pain or bleeding-related therapeutic categories. The exact product indication should be verified from its approved product information.
Moruf lists FERJOY-PCO and FERJOY-IN among its PCOS-related and women's healthcare formulations. Their compositions differ, so distributors should review each product separately.
Progesterone and progestogen medicines are prescribed for selected reproductive and gynaecological conditions. Their use depends on the specific medicine, diagnosis and treatment plan.
Review the company's product range, compositions, manufacturing and quality documentation, product permissions, supply arrangements, promotional support, pricing and written monopoly terms.
Some gynaecology franchise portfolios include hormonal medicines such as progesterone and progestogen formulations, as well as hormonal contraceptives. The available products depend on the pharmaceutical company's catalogue.
Menstrual health and hormonal care cover several important areas of women's healthcare, from menstrual pain and heavy bleeding to PCOS-related management and prescribed hormonal treatments.
For pharmaceutical distributors, understanding these categories is an important part of evaluating a Gynae PCD Pharma Franchise opportunity. A carefully selected product portfolio, supported by accurate product information, reliable supply and transparent business terms, can provide a strong foundation for operating in the specialised gynaecology segment.
Moruf Lifesciences offers a range of products across these categories, giving prospective franchise partners a portfolio to explore as they assess opportunities in women's healthcare.
Medical and product information note: This article is intended for pharmaceutical business awareness and general education. It does not replace professional medical advice. Medicines, including hormonal preparations, contraceptives and medicines for menstrual bleeding or pain, should be prescribed and used only under the guidance of a qualified healthcare professional. Always verify current product compositions, approved indications and regulatory documentation before promotion or distribution.
Contact information
Name – Moruf Lifesciences
Phone Numbers – +91-9888163636
Email - moruflifesciences0719@gmail.com
Address: SCO 5-6, Wadhawa Nagar, Near Hotel Sunpark, Kalka Highway, Zirakpur, Punjab, India – 140603
Read more about -